AimedBio, a company specializing in the development of antibody-drug conjugates (ADCs), announced on the 24th that it has passed the technology assessment for a special technology listing.
AimedBio obtained A and A grades from two technology evaluation agencies designated by the Korea Exchange, proving both its excellent technological capabilities and high business viability. This assessment fulfilled the main requirements for a special technology listing, and from the second half of the year, the company plans to begin the full process for a KOSDAQ listing.
It is noted that the company's high scores in the technology assessment were significantly influenced by the technology transfer contract signed last year with Biohaven in the U.S. AimedBio transferred the brain tumor treatment candidate 'AMB302' to Biohaven. On the 9th, it also entered into a joint development contract with SK Plasma for the difficult-to-treat cancer candidate 'AMB303.'
AimedBio is a drug venture that was spun off from Samsung Seoul Hospital in 2018 by Professor Nam Do-hyun of the neurosurgery department. Professor Nam currently serves as the chief technology officer (CTO), responsible for the company's technology development. In 2023, it gained market attention after receiving investment from the Samsung Life Science Fund.
AimedBio's designated underwriter for its KOSDAQ listing is Mirae Asset Securities, with the goal of submitting a securities registration statement within the year.
Heo Nam-gu, CEO of AimedBio, stated, "This technology assessment officially recognizes AimedBio's technological completeness and global capabilities," adding, "Through the listing, we aim to enhance our growth momentum and leap forward as a global bio corporation leading innovative cancer drug development."